CN102711825A - 用于施用EpCAMxCD3双特异性抗体的给药方案 - Google Patents
用于施用EpCAMxCD3双特异性抗体的给药方案 Download PDFInfo
- Publication number
- CN102711825A CN102711825A CN2010800523771A CN201080052377A CN102711825A CN 102711825 A CN102711825 A CN 102711825A CN 2010800523771 A CN2010800523771 A CN 2010800523771A CN 201080052377 A CN201080052377 A CN 201080052377A CN 102711825 A CN102711825 A CN 102711825A
- Authority
- CN
- China
- Prior art keywords
- bispecific antibody
- dose
- epcamxcd3 bispecific
- period
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24365109P | 2009-09-18 | 2009-09-18 | |
| EP09170715 | 2009-09-18 | ||
| US61/243,651 | 2009-09-18 | ||
| EP09170715.8 | 2009-09-18 | ||
| US34414710P | 2010-06-01 | 2010-06-01 | |
| EP10164596 | 2010-06-01 | ||
| EP10164596.8 | 2010-06-01 | ||
| US61/344,147 | 2010-06-01 | ||
| PCT/EP2010/063795 WO2011033105A1 (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102711825A true CN102711825A (zh) | 2012-10-03 |
Family
ID=43127167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800523771A Pending CN102711825A (zh) | 2009-09-18 | 2010-09-20 | 用于施用EpCAMxCD3双特异性抗体的给药方案 |
Country Status (15)
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135968A (zh) * | 2015-08-28 | 2018-06-08 | 阿穆尼克斯运营公司 | 嵌合多肽组装体及其制备和使用方法 |
| CN108602891A (zh) * | 2016-03-30 | 2018-09-28 | 霍斯特·林德霍费尔 | 治疗尿道恶性肿瘤的多特异性抗体 |
| CN111356700A (zh) * | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| CN112807429A (zh) * | 2015-11-19 | 2021-05-18 | 雷维托普有限公司 | 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
| AR089114A1 (es) | 2011-12-09 | 2014-07-30 | Amgen Res Munich Gmbh | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| WO2014131694A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US11046763B2 (en) * | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第viii因子を除去する方法 |
| CA3238406A1 (en) * | 2021-11-19 | 2023-05-25 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
-
2010
- 2010-09-20 RU RU2012115480/15A patent/RU2012115480A/ru not_active Application Discontinuation
- 2010-09-20 EP EP10755167A patent/EP2477653A1/en not_active Withdrawn
- 2010-09-20 JP JP2012529298A patent/JP2013505223A/ja active Pending
- 2010-09-20 CA CA2774732A patent/CA2774732A1/en not_active Abandoned
- 2010-09-20 SG SG10201405434VA patent/SG10201405434VA/en unknown
- 2010-09-20 NZ NZ598601A patent/NZ598601A/en not_active IP Right Cessation
- 2010-09-20 WO PCT/EP2010/063795 patent/WO2011033105A1/en not_active Ceased
- 2010-09-20 AU AU2010297258A patent/AU2010297258A1/en not_active Abandoned
- 2010-09-20 KR KR1020127007677A patent/KR20120083359A/ko not_active Withdrawn
- 2010-09-20 CN CN2010800523771A patent/CN102711825A/zh active Pending
- 2010-09-20 US US13/496,836 patent/US20120244161A1/en not_active Abandoned
- 2010-09-20 BR BR112012008345A patent/BR112012008345A2/pt not_active IP Right Cessation
- 2010-09-20 IN IN3172DEN2012 patent/IN2012DN03172A/en unknown
- 2010-09-20 SG SG2012016044A patent/SG179027A1/en unknown
- 2010-09-20 MX MX2012003175A patent/MX2012003175A/es not_active Application Discontinuation
-
2012
- 2012-03-14 IL IL218637A patent/IL218637A0/en unknown
Non-Patent Citations (1)
| Title |
|---|
| KLAUS BRISCHWEIN,ET AL: "MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors", 《MOLECULAR IMMUNOLOGY》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135968A (zh) * | 2015-08-28 | 2018-06-08 | 阿穆尼克斯运营公司 | 嵌合多肽组装体及其制备和使用方法 |
| CN112807429A (zh) * | 2015-11-19 | 2021-05-18 | 雷维托普有限公司 | 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用 |
| US12673993B2 (en) | 2015-11-19 | 2026-07-07 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN108602891A (zh) * | 2016-03-30 | 2018-09-28 | 霍斯特·林德霍费尔 | 治疗尿道恶性肿瘤的多特异性抗体 |
| CN111356700A (zh) * | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| US11744892B2 (en) | 2017-09-08 | 2023-09-05 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US11744893B2 (en) | 2017-09-08 | 2023-09-05 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US12478673B2 (en) | 2017-09-08 | 2025-11-25 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| IL218637A0 (en) | 2012-05-31 |
| JP2013505223A (ja) | 2013-02-14 |
| SG179027A1 (en) | 2012-04-27 |
| CA2774732A1 (en) | 2011-03-24 |
| AU2010297258A1 (en) | 2012-03-29 |
| SG10201405434VA (en) | 2014-10-30 |
| US20120244161A1 (en) | 2012-09-27 |
| NZ598601A (en) | 2014-05-30 |
| MX2012003175A (es) | 2012-04-11 |
| KR20120083359A (ko) | 2012-07-25 |
| EP2477653A1 (en) | 2012-07-25 |
| WO2011033105A1 (en) | 2011-03-24 |
| IN2012DN03172A (cg-RX-API-DMAC7.html) | 2015-09-25 |
| BR112012008345A2 (pt) | 2016-08-09 |
| RU2012115480A (ru) | 2013-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120244161A1 (en) | DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY | |
| US12570757B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| WO2021228178A1 (en) | Compositions and methods for treating cancer | |
| US20240109972A1 (en) | Antibody and taxane combination therapy | |
| WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| TW201322985A (zh) | 由EpCAMxCD3雙特異性抗體引起之不良作用的預防 | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| JP7862570B2 (ja) | がんの治療のための併用療法 | |
| EP4611905A1 (en) | Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab | |
| JP2025542297A (ja) | 肺癌の組み合わせ療法 | |
| US20260085119A1 (en) | Methods for treating cancer using anti-ctla4 antibodies | |
| RU2833461C1 (ru) | Способы лечения рака шейки матки путем введения инибитора pd-1 | |
| HK40112915A (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| EP4392068A1 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| CN118251234A (zh) | 抗半乳糖凝集素-9抗体及其治疗用途 | |
| CN121693347A (zh) | 使用可活化抗ctla4抗体与pembrolizumab组合治疗癌症的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Munich, Germany Applicant after: Amgen Research Munich GmbH Address before: Munich, Germany Applicant before: Micromet AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MICROMET AG TO: AMGEN RESEARCH MUNICH GMBH |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121003 |